What Is Atossa Therapeutics, Inc. (ATOS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Atossa Therapeutics, Inc.'s intrinsic value is estimated at $4.58, suggesting a +87.9% average upside from the current price of $2.44. While 4 models see room for appreciation, model agreement is not unanimous as 1 model flags potential overvaluation. Model dispersion is worth noting: First Chicago targets $14.39 (+489.9%), versus ML-RIV at $0.52 (-78.6%). This +568.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ATOS?
7 of 13 models are currently active for ATOS. Of these, 4 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates ATOS's intrinsic value at $2.39, implying -2.0% downside from the current price. See which stocks rank higher →
How Does ATOS Rank in Biotechnology?
Among 76 Biotechnology stocks, ATOS ranks #47 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
As a biotechnology enterprise, Atossa Therapeutics, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ATOS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ATOS a Value Trap?
CirclFi's Value Trap algorithm assigns ATOS a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Atossa Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Atossa Therapeutics, Inc.'s fundamental quality profile registers 4.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +568.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ATOS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ATOS's 7 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad